Teva’s “blockbuster” treatment pipeline

Israel’s Teva expects FDA approval in 2017 for seven innovative treatments. They include for chronic migraine, multiple sclerosis, Huntington’s Disease and tardive dyskinesia (movement disorder).

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *